Access to Oral Osteoporosis Drugs Among Female Medicare Part D Beneficiaries

Access barriers for drug therapy initiation may be driven by factors other than patients' OOP costs. These results suggest that improved osteoporosis treatment requires a more comprehensive approach that goes beyond payment policies.